ALK and non-small cell lung carcinoma: Patients with EGFR/ALK wild‐type metastatic NSCLC and without disease progression (PD) in the initial treatment were randomly assigned to receive durvalumab combined with olaparib or durvalumab monotherapy as first‐line treatment.